Main Products/ Services/ Pipelines & Platforms
DCB is dedicated to advancing Taiwan's biotechnology industry through focused efforts in the research and development (R&D) of preclinical development and translational medicine research for novel drugs and treatments. Additionally, the organization is actively involved in drug commercialization and business development.
DCB’s Current Pipeline Biologics • Immuno-oncology   ▪ Preclinical    ♦ CD73 mAb (DCBPR2201) / NSCLC    ♦ Globo H CAR-T / Gastric Cancer   ▪ Validation and Optimization    ♦ PD-L1 mAb    ♦ Tim-3 mAb    ♦ CSF-1R mAb • Oncology   ▪ IND    ♦ Raf Inhibitor / Melanoma   ▪ Preclinical    ♦ NTSR1 ADC (DCBAD2301) / Head and Neck Cancer    ♦ B7-H3 ADC (DCBAD2303) / B7-H3-positive Tumors
Pharmaceutics • Oncology   ▪ Preclinical    ♦ FPR1 Inhibitor / Neutrophil Related Inflammatory Disease
Platforms • Development of Protein-degrader Drugs Against Cancer • mRNA-LNP Production Platform • Full Human Synthetic Library for Antibody Drug Discovery
Business Interests
Out-Licensing, Collaborative R&D
Contact Info
Ching-Hsu Yang
Project Manager
+886-2-7700-3800 ext.5293
ch.yang@dcb.org.tw